Foresite Capital Fund V L.P. 13D and 13G filings for Kinnate Biopharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-05 4:15 pm Sale | 2024-04-03 | 13D | Kinnate Biopharma Inc. KNTE | Foresite Capital Fund V L.P. | 0 0.000% | -13,779,062 (Position Closed) | Filing |
| 2024-02-22 4:39 pm Unchanged | 2024-02-16 | 13D | Kinnate Biopharma Inc. KNTE | Foresite Capital Fund V L.P. | 13,779,062 29.200% | 0 (Unchanged) | Filing |
| 2023-11-17 08:00 am Unchanged | 2023-11-17 | 13D | Kinnate Biopharma Inc. KNTE | Foresite Capital Fund V L.P. | 13,779,062 29.200% | 0 (Unchanged) | Filing |
| 2023-11-14 4:30 pm Purchase | 2023-11-13 | 13D | Kinnate Biopharma Inc. KNTE | Foresite Capital Fund V L.P. | 13,779,062 29.200% | 13,779,062 (New Position) | Filing |